We claim,

1. A stabilized drug delivery system for proton pump inhibitors which comprises benzimidazole compounds or their salts, preferably Rabeprazole or its salts and pharmaceutically acceptable excipients in powder form, which is reconstitutable in a parenterally acceptable solvent to form an injectable solution.
2. The drug delivery system as claimed in claim 1, wherein the said salts of Rabeprazole may be in the form of alkaline metal salts or alkaline earth metal salts.
3. The drug delivery system as claimed in claims 1 and 2, wherein the said alkaline metal salts may be sodium or potassium.
4. The drug delivery system as claimed in claims 1 and 2, wherein the said alkaline earth metal salts may be calcium or magnesium.
5. The drug delivery system as claimed in claim 1, wherein the said system comprises Rabeprazole sodium, mannitol, alkaline compounds and water for injection.
6. The drug delivery system as claimed in claim 1, wherein the said system is preferably in the form of stabilized lyophilized injection.
7. The drug delivery system as claimed in claim 5, wherein the said alkaline compound is sodium hydroxide.
8. The drug delivery system as claimed in claims 1 to 7, wherein the pH of the said system is between 9 – 11.
9. The drug delivery system as claimed in claims 1 to 8, wherein the said Rabeprazole in the said reconstitutable powder form is in the range of 8% to 77%, preferably 19 – 62% by weight of the total composition.
10. The drug delivery system as claimed in claims 1 to 8, wherein the said Mannitol in the said reconstitutable powder form is in the range of 19% to 88%, preferably 30% - 88% by weight of the total composition.
11. A process for preparation of the said drug delivery system which comprises dissolving sodium hydroxide in Water For Injection to adjust the pH above 12.0, adding Mannitol and Rabeprazole sodium to the above said solution maintaining the pH of the said solution; making up the volume with water for injection; filtering the said solution aseptically through 0.22μ filter paper;

filling the said filtered solution in previously sterilized 10ml vials; maintaining the temperature of the injectable solution at 10°C ± 2°C throughout the process; loading the vials into lyophilizer after partial bunging and lyophilizing the said solution to obtain the said powder form of drug delivery system which is reconstitutable in a parenterally acceptable solvent to form an injectable solution.

12. The drug delivery system for proton pump inhibitor prepared by process as claimed in claim 11.
13. A novel drug delivery system for proton pump inhibitors as substantially described herein with reference to foregoing example.
14. A process for preparation of the said drug delivery system as substantially described herein with reference to foregoing example.